Amibegron

Drug Profile

Amibegron

Alternative Names: SR 58611; SR 58611A

Latest Information Update: 12 Aug 2008

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antidepressants; Carboxylic acids; Naphthalenes; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Generalised anxiety disorder; Irritable bowel syndrome; Major depressive disorder; Obesity

Most Recent Events

  • 31 Jul 2008 Discontinued - Phase-III for Generalised anxiety disorder in Chile (unspecified route)
  • 31 Jul 2008 Discontinued - Phase-III for Generalised anxiety disorder in Australia (unspecified route)
  • 31 Jul 2008 Discontinued - Phase-III for Generalised anxiety disorder in South Africa (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top